Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$79.00

0.229 (0.29%)

14:03
10/19/16
10/19
14:03
10/19/16
14:03

FDA grants accelerated approval to Eli Lilly's Lartruvo for soft tissue cancer

The U.S. FDA granted accelerated approval to Lartruvo, or olaratumab, with doxorubicin to treat adults with certain types of soft tissue sarcoma, which are cancers that develop in muscles, fat, tendons or other soft tissues. Lartruvo is approved for use with the FDA-approved chemotherapy drug doxorubicin for the treatment of patients with STS who cannot be cured with radiation or surgery and who have a type of STS for which an anthracycline is an appropriate treatment. "This is the first new therapy approved by the FDA for the initial treatment of soft tissue sarcoma since doxorubicin's approval more than 40 years ago," the agency noted. Lartruvo has "serious risks" including infusion-related reactions and embryo-fetal harm, the FDA added. Lartruvo is marketed by Eli Lilly.

  • 25

    Oct

  • 06

    Nov

LLY Eli Lilly
$79.00

0.229 (0.29%)

09/27/16
GSCO
09/27/16
UPGRADE
Target $95
GSCO
Buy
Eli Lilly upgraded to Buy from Neutral at Goldman
Goldman analyst Jami Rubin upgraded Eli Lilly to Buy and increased its price target to $95 from $89 saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. Rubin projects $12.5B of new product sales by 2020 and double digit earnings growth over the next five years, even without Sola. The analyst sees a 35%, up from 25%, probability of success for Sola with a bull case scenario that can lead to almost $7.5B in peak sales and "super charge" earnings. Even without Sola, Rubin sees favorable risk/reward given durability of earnings and said it is the least exposed to above-CPI price increases.
09/27/16
09/27/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Buy from Neutral at Goldman with analyst Jami Rubin saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. 2. AutoZone (AZO) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Simeon Gutman saying the company is at a positive inflection in 7 year and older vehicles, which is strongly correlated to same-store-sales. 3. Consolidated Edison (ED) upgraded to Hold from Sell at Evercore ISI with analyst Greg Gordon saying the joint settlement proposal filed in the CECONY rate case mitigates downside risk. 4. Crown Holdings (CCK) upgraded on multiple catalysts at BMO Capital with analyst Mark Wilde citing valuation, his belief that the company will resume returning cash to shareholders in 2017, and his belief that the company's results should be boosted by " a wave of domestic and offshore expansion projects." 5. Francesca's (FRAN) upgraded to Buy from Hold at Stifel with analyst Richard Jaffe saying the company's "appealing merchandise" makes it very likely that its sales will grow going forward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.

TODAY'S FREE FLY STORIES

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:11
04/25/17
04/25
18:11
04/25/17
18:11
Hot Stocks
Pain Therapeutics sees completing additional Remoxy studies by year end »

"As previously…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:10
04/25/17
04/25
18:10
04/25/17
18:10
Hot Stocks
Breaking Hot Stocks news story on Pain Therapeutics »

Pain Therapeutics backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:09
04/25/17
04/25
18:09
04/25/17
18:09
Earnings
Pain Therapeutics reports Q1 EPS (6c), one estimate (6c) »

Reports Q1 net cash usage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PHG

Philips

$34.69

0.14 (0.41%)

18:04
04/25/17
04/25
18:04
04/25/17
18:04
Hot Stocks
Philips Lighting repurchases 3.5M shares for roughly EUR101M »

Philips Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBF

PBF Energy

$22.56

0.26 (1.17%)

, WDR

Waddell & Reed

$17.92

-0.14 (-0.78%)

18:03
04/25/17
04/25
18:03
04/25/17
18:03
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

PBF

PBF Energy

$22.56

0.26 (1.17%)

WDR

Waddell & Reed

$17.92

-0.14 (-0.78%)

SWC

Stillwater Mining

$17.99

0.09 (0.50%)

SBGL

Sibanye Gold

$8.14

-0.28 (-3.33%)

ARI

Apollo Commercial

$18.93

0.05 (0.26%)

ZLTQ

ZELTIQ

$56.49

-0.005 (-0.01%)

AGN

Allergan

$238.22

1.24 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 11

    May

  • 31

    May

FRO

Frontline

$6.73

0.06 (0.90%)

, DHT

DHT Holdings

$4.67

0.04 (0.86%)

18:02
04/25/17
04/25
18:02
04/25/17
18:02
Hot Stocks
Frontline says makes new offer to DHT Holdings »

Frontline (FRO) issued…

FRO

Frontline

$6.73

0.06 (0.90%)

DHT

DHT Holdings

$4.67

0.04 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMBI

First Midwest

$24.11

0.16 (0.67%)

18:01
04/25/17
04/25
18:01
04/25/17
18:01
Earnings
First Midwest reports Q1 adjusted EPS 34c, consensus 33c »

Net interest income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 17

    May

FRO

Frontline

$6.73

0.06 (0.90%)

, DHT

DHT Holdings

$4.67

0.04 (0.86%)

18:00
04/25/17
04/25
18:00
04/25/17
18:00
Hot Stocks
Breaking Hot Stocks news story on Frontline, DHT Holdings »

Frontline says makes new…

FRO

Frontline

$6.73

0.06 (0.90%)

DHT

DHT Holdings

$4.67

0.04 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFLY

Shutterfly

$51.46

0.18 (0.35%)

17:58
04/25/17
04/25
17:58
04/25/17
17:58
Hot Stocks
Shutterfly to retire MyPublisher brand and cite in Q2 »

Comment from company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

HBNC

Horizon Bancorp

$27.24

0.37 (1.38%)

17:57
04/25/17
04/25
17:57
04/25/17
17:57
Earnings
Horizon Bancorp reports Q1 adjusted EPS 34c, consensus 41c »

Reports Q1 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXP

Boston Properties

$133.97

1.18 (0.89%)

17:57
04/25/17
04/25
17:57
04/25/17
17:57
Earnings
Breaking Earnings news story on Boston Properties »

Boston Properties sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

KMT

Kennametal

$40.48

1.15 (2.92%)

17:56
04/25/17
04/25
17:56
04/25/17
17:56
Hot Stocks
Kennametal sees restructuring yielding annual pre-tax savings $165M-$180M »

"Restructuring…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

  • 30

    May

  • 31

    May

BXP

Boston Properties

$133.97

1.18 (0.89%)

17:56
04/25/17
04/25
17:56
04/25/17
17:56
Earnings
Breaking Earnings news story on Boston Properties »

Boston Properties sees Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

BXP

Boston Properties

$133.97

1.18 (0.89%)

17:55
04/25/17
04/25
17:55
04/25/17
17:55
Earnings
Boston Properties reports Q1 EPS 63c, consensus 55c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

ZIXI

ZixCorp

$5.21

-0.14 (-2.62%)

, IRBT

iRobot

$69.14

-0.12 (-0.17%)

17:54
04/25/17
04/25
17:54
04/25/17
17:54
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

ZIXI

ZixCorp

$5.21

-0.14 (-2.62%)

IRBT

iRobot

$69.14

-0.12 (-0.17%)

EW

Edwards Lifesciences

$98.92

0.96 (0.98%)

WYNN

Wynn Resorts

$118.22

2.65 (2.29%)

JNPR

Juniper

$27.78

-0.49 (-1.73%)

CMG

Chipotle

$471.76

2.97 (0.63%)

ASYS

Amtech Systems

$5.50

-0.05 (-0.90%)

PETX

Aratana Therapeutics

$6.04

-0.07 (-1.15%)

DECK

Deckers Brands

$58.74

0.4 (0.69%)

COST

Costco

$172.68

0.35 (0.20%)

X

U.S. Steel

$31.11

-0.09 (-0.29%)

CREE

Cree

$24.82

0.07 (0.28%)

NUVA

NuVasive

$76.94

0.59 (0.77%)

DFS

Discover

$67.28

0.37 (0.55%)

ULTI

Ultimate Software

$210.91

0.99 (0.47%)

COF

Capital One

$85.58

0.9 (1.06%)

ILMN

Illumina

$181.50

1.3 (0.72%)

CHRW

C.H. Robinson

$77.70

0.11 (0.14%)

FLXN

Flexion

$25.96

-0.25 (-0.95%)

NBIX

Neurocrine

$53.62

1.84 (3.55%)

MPW

Medical Properties Trust

$13.84

0.03 (0.22%)

CCI

Crown Castle

$94.27

-0.44 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 02

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 04

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 15

    May

  • 18

    May

  • 18

    May

  • 25

    May

  • 31

    May

  • 06

    Jun

  • 06

    Jun

  • 06

    Jun

  • 08

    Jun

  • 08

    Jun

  • 06

    Oct

  • 26

    Apr

  • 26

    Apr

SMBK

SmartFinancial

$22.31

0.61 (2.81%)

17:52
04/25/17
04/25
17:52
04/25/17
17:52
Earnings
SmartFinancial reports Q1 EPS 19c, two estimates 21c »

Reports Q1 NII $9.8M vs.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

SXT

Sensient

$83.27

1.18 (1.44%)

17:51
04/25/17
04/25
17:51
04/25/17
17:51
Earnings
Sensient reafirms FY17 adjusted EPS view $3.35-$3.45, consensus $3.41 »

Sensient updated FY17 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

FTI

TechnipFMC

$32.12

0.23 (0.72%)

17:51
04/25/17
04/25
17:51
04/25/17
17:51
Hot Stocks
TechnipFMC awarded subsea contract for ExxonMobil Liza in Guyana »

Technip (FTI) has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

SXT

Sensient

$83.27

1.18 (1.44%)

17:50
04/25/17
04/25
17:50
04/25/17
17:50
Earnings
Sensient reports Q1 adjusted EPS 82c, consensus 82c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

ZIXI

ZixCorp

$5.21

-0.14 (-2.62%)

17:41
04/25/17
04/25
17:41
04/25/17
17:41
Hot Stocks
ZixCorp announces up to $10M share repurchase program »

Zix Corporation announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 03

    May

UMBF

UMB Financial

$77.08

0.195 (0.25%)

17:35
04/25/17
04/25
17:35
04/25/17
17:35
Hot Stocks
UMB Financial approves 2M shares repurchase plan »

UMB Financial approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 15

    May

MSA

MSA Safety

$73.25

0.9 (1.24%)

17:35
04/25/17
04/25
17:35
04/25/17
17:35
Earnings
MSA Safety reports Q1 cont ops EPS 37c, consensus 50c »

Reports Q1 revenue $266M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 11

    May

OESX

Orion Energy

$1.79

-0.04 (-2.19%)

17:32
04/25/17
04/25
17:32
04/25/17
17:32
Earnings
Orion Energy sees Q4 revenue $15.1-$15.5M, consensus $20.72M »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

RCII

Rent-A-Center

$10.86

-0.15 (-1.36%)

17:29
04/25/17
04/25
17:29
04/25/17
17:29
Hot Stocks
Engaged Capital responds to Rent-A-Center »

Engaged Capital issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

LMT

Lockheed Martin

$270.02

-6.19 (-2.24%)

17:28
04/25/17
04/25
17:28
04/25/17
17:28
Hot Stocks
Lockheed Martin awarded $109.5M government contract »

Lockheed Martin Corp.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 31

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.